Preclinical antileukemia activity of JNJ-26481585, a potent second-generation histone deacetylase inhibitor

Leukemia Research

Volumn 34, Issue 2, 2010, Pages 221-228

  Tong, Wei Gang ^a   Wei, Yue ^a   Stevenson, William ^a   Kuang, Shao Qing ^a   Fang, Zhihong ^a   Zhang, Ming ^a   Arts, Janine ^b   Garcia Manero, Guillermo ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Ortho Biotech Oncology Research and Development   (Belgium)

Author keywords

Apoptosis; Epigenetic therapy; HDAC inhibitor; JNJ 26481585; Leukemia

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTILEUKEMIC AGENT; AZACITIDINE; CLOFARABINE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID DERIVATIVE; IDARUBICIN; IMATINIB; JNJ 26481585; UNCLASSIFIED DRUG; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL STRAIN HL 60; CELL STRAIN U937; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG SCREENING; EPIGENETICS; EX VIVO STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL LINE; MOLECULAR MECHANICS; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; AZACITIDINE; DRUG EVALUATION, PRECLINICAL; DRUG SYNERGISM; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; LEUKEMIA; TUMOR CELLS, CULTURED;

EID: 75049084999     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2009.07.024     Document Type: Article

References (31)

1. Csordas A. On the biological role of histone acetylation. Biochem J 265 (1990) 23-38
2. Grunstein M. Histone acetylation in chromatin structure and transcription. Nature 389 (1997) 349-352
3. Hassig C.A., and Schreiber S.L. Nuclear histone acetylases and deacetylases and transcriptional regulation: HATs off to HDACs. Curr Opin Chem Biol 1 (1997) 300-308
4. Kouzarides T. Histone acetylases and deacetylases in cell proliferation. Curr Opin Gene Dev 9 (1999) 40-48
5. Duvic M., Talpur R., Ni X., Zhang C., Hazarika P., Kelly C., et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid. SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 109 (2007) 31-39
6. Garcia-Manero G., Assouline S., Cortes J., Estrov Z., Kantarjian H., Yang H., et al. Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia. Blood 112 (2008) 981-989
7. Garcia-Manero G., Kantarjian H.M., Sanchez-Gonzalez B., Yang H., Rosner G., Verstovsek S., et al. Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemia. Blood 108 (2006) 3271-3279
8. Gojo I., Jiemjit A., Trepel J.B., Sparreboom A., Figg W.D., Rollins S., et al. Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. Blood 109 (2007) 2781-2790
9. Giles F., Fischer T., Cortes J., Garcia-Manero G., Beck J., Ravandi F., et al. A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res 12 (2006) 4628-4635
10. Kang J., Zhang Y., Chen J., Chen H., Lin C., Wang Q., et al. Nickel-induced histone hypoacetylation: the role of reactive oxygen species. Toxicol Sci 74 (2003) 279-286
11. Rosato R.R., and Grant S. Histone deacetylase inhibitors in cancer therapy. Cancer Biol Ther 2 (2003) 30-37
12. Dai Y., Rahmani M., Dent P., and Grant S. Blockade of histone deacetylase inhibitor-induced RelA/p65 acetylation and NF-kappaB activation potentiates apoptosis in leukemia cells through a process mediated by oxidative damage, XIAP downregulation, and c-Jun N-terminal kinase 1 activation. Mol Cell Biol 25 (2005) 5429-5444
13. Place R.F., Noonan E.J., and Giardina C. HDAC inhibition prevents NF-kappa B activation by suppressing proteasome activity: down-regulation of proteasome subunit expression stabilizes I kappa B alpha. Biochem Pharm 70 (2005) 394-406
14. Fulda S. Modulation of TRAIL-induced apoptosis by HDAC inhibitors. Curr Cancer Drug Targets 8 (2008) 132-140
15. Mariadason J.M. HDACs and HDAC inhibitors in colon cancer. Epigenetics 3 (2008) 28-37
16. Oh M., Choi I.K., and Kwon H.J. Inhibition of histone deacetylase1 induces autophagy. Biochem Biophys Res Commun 369 (2008) 1179-1183
17. Shao Y., Gao Z., Marks P.A., and Jiang X. Apoptotic and autophagic cell death induced by histone deacetylase inhibitors. Proc Natl Acad Sci USA 101 (2004) 18030-18035
18. Yamamoto S., Tanaka K., Sakimura R., Okada T., Nakamura T., Li Y., et al. Suberoylanilide hydroxamic acid (SAHA) induces apoptosis or autophagy-associated cell death in chondrosarcoma cell lines. Anticancer Res 28 (2008) 1585-1591
19. Arts J., Marien A., King P., Floren W., Belien A., Janssen L., et al. JNJ-26481585: a novel "second-generation" oral pan-histone deacetylase (HDAC) inhibitor showing broad-spectrum preclinical antitumor activity against solid and haematological malignancies. AACR proceedings (2008) [abstract #2444]
20. Yang H., Hoshino K., Sanchez-Gonzalez B., Kantarjian H., and Garcia-Manero G. Antileukemia activity of the combination of 5-aza-2′-deoxycytidine with valproic acid. Leukemia Res 29 (2005) 739-748
21. Tong W.G., Ding X.Z., Talamonti M.S., Bell R.H., and Adrian T.E. LTB4 stimulates growth of human pancreatic cancer cells via MAPK and PI-3 kinase pathways. Biochem Biophys Res Commun 335 (2005) 949-956
22. Greco W.R., Bravo G., and Parsons J.C. The search for synergy: a critical review from a response surface perspective. Pharmacol Rev 47 (1995) 331-385
23. Ocker M., and Schneider-Stock R. Histone deacetylase inhibitors: signalling towards p21cip1/waf1. Int J Biochem Cell Biol 39 (2007) 1367-1374
24. Sanchez-Gonzalez B., Yang H., Bueso-Ramos C., Hoshino K., Quintas-Cardama A., Richon V.M., et al. Antileukemia activity of the combination of an anthracycline with a histone deacetylase inhibitor. Blood 108 (2006) 1174-1182
25. Thomas D.A., Faderl S., Cortes J., O'Brien S., Giles F.J., Kornblau S.M., et al. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood 103 (2004) 4396-4407
26. Siu L.L., Pili R., Duran I., Messersmith W.A., Chen E.X., Sullivan R., et al. Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors. J Clin Oncol 26 (2008) 1940-1947
27. Garcia-Manero G., Yang H., Bueso-Ramos C., Ferrajoli A., Cortes J., Wierda W.G., et al. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood 111 (2008) 1060-1066
28. Fournel M., Bonfils C., Hou Y., Yan P.T., Trachy-Bourget M.C., Kalita A., et al. MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo. Mol Cancer Ther 7 (2008) 759-768
29. Shao J., Gao Z., Marks P.A., and Jiang X. Apoptotic and autophagic cell death induced by histone deacetylase inhibitors. Proc Natl Acad Sci USA 101 (2004) 18030-18035
30. Kantarjian H., Oki Y., Garcia-Manero G., Huang X., O'Brien S., Cortes J., et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 109 (2007) 52-57
31. Kaminskas E., Farrell A.T., Wang Y.C., Sridhara R., and Pazdur R. FDA drug approval summary: azacytidine (5-azacytidine, Vidaza) for injectable suspension. Oncologist 10 (2005) 176-182